

Healthy Volunteers

**A study to look at how safe different doses of GDC-0334 were for healthy people and how this medicine was processed through the body**

A Study of the Safety, Tolerability, Pharmacokinetics and Pharmacodynamic Effects of Single and Multiple Ascending Doses of GDC-0334 and the Effect of Food on the Pharmacokinetics of GDC-0334 in Healthy Adult Participants

**Trial Status**  
Terminated

**Trial Runs In**  
1 Countries

**Trial Identifier**  
NCT03381144 2017-003498-33  
GB40223

*The source of the below information is the publicly available website ClinicalTrials.gov. It has been summarised and edited into simpler language.*

***Trial Summary:***

This is a randomized, double-blind, placebo-controlled, single-center, three-part study designed to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamic effects of single and multiple ascending doses of GDC-0334 and the effect of food on the pharmacokinetics of GDC-0334 in healthy adult participants.

**Genentech, Inc.**  
Sponsor

**Phase 1**  
Phase

**NCT03381144 2017-003498-33 GB40223**  
Trial Identifiers

***Eligibility Criteria:***

**Gender**  
All

**Age**  
≥ 18 Years & ≤ 55 Years

**Healthy Volunteers**  
Accepts Healthy Volunteers

GDC-0334 is a new medicine for the treatment of patients with severe asthma. This study was the first time that humans got GDC-0334. People (healthy volunteers) received different doses of the study medicine to find out which dose was safe.